Patents Assigned to Auragen, Inc.
  • Patent number: 5661132
    Abstract: A DNA molecule encoding a secretable mature epidermal growth factor (EGF) polypeptide is delivered to a skin wound. The cells that take up the recombinant DNA construct express soluble EGF that is secreted into surrounding fluid. The presence of the EGF accelerates, by a statistically significant amount, the healing time of a wound treated in this manner.The DNA molecule can be a genetic construction that expresses an EGF encoding portion that differs from the naturally occurring EGF precursor gene in that the only coding region retained from the precursor gene is that of the mature EGF polypeptide. Amino-terminal EGF-like repeats and the carboxy-terminal hydrophobic sequence that anchors natural EGF to the cell membrane are not present in the genetic construction.
    Type: Grant
    Filed: November 22, 1994
    Date of Patent: August 26, 1997
    Assignee: Auragen, Inc.
    Inventors: Elof Eriksson, Christophe Andree, William F. Swain, Michael D. Macklin